Stevanato Group S.p.A. (STVN)
NYSE: STVN · IEX Real-Time Price · USD
20.71
-0.20 (-0.96%)
May 17, 2024, 4:00 PM EDT - Market closed
Stevanato Group Employees
Stevanato Group had 5,634 employees on December 31, 2023. The number of employees increased by 374 or 7.11% compared to the previous year.
Employees
5,634
Change (1Y)
374
Growth (1Y)
7.11%
Revenue / Employee
$209,010
Profits / Employee
$26,273
Market Cap
5.67B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 5,634 | 374 | 7.11% |
Dec 31, 2022 | 5,260 | 608 | 13.07% |
Dec 31, 2021 | 4,652 | 308 | 7.09% |
Dec 31, 2020 | 4,344 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Acadia Healthcare Company | 23,500 |
DENTSPLY SIRONA | 15,000 |
Organon & Co. | 10,000 |
Exelixis | 1,310 |
Glaukos | 907 |
Lantheus Holdings | 834 |
ImmunityBio | 628 |
BridgeBio Pharma | 550 |
STVN News
- 21 hours ago - Stevanato Being Investigated on Behalf of Stevanato Group S.p.A. Investors. - Accesswire
- 9 days ago - Stevanato Group Reports Financial Results for the First Quarter of 2024 - Business Wire
- 16 days ago - Stevanato Group to Present at the Bank of America Securities Healthcare Conference - Business Wire
- 22 days ago - Stevanato Group to Report First Quarter 2024 Financial Results on May 9, 2024 - Business Wire
- 7 weeks ago - Stevanato Group Announces Closing of Upsized Public Offering of Ordinary Shares and Exercise in Full of the Underwriters' Option to Purchase Additional Ordinary Shares - Business Wire
- 2 months ago - Stevanato Group Announces Pricing of Upsized Public Offering of Ordinary Shares - Business Wire
- 2 months ago - Stevanato Group Announces Public Offering of Ordinary Shares - Business Wire
- 2 months ago - Stevanato Group to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum - Business Wire